Study #2023-0871
An open-label phase 1/2a study of GV20-0251 monotherapy and GV20-0251 in combination with Pembrolizumab in participants with advanced and/or refractory solid tumor malignancies.
MD Anderson Study Status
Enrolling
Treatment Agent
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
Description
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Study phase:
Physician name:
Aung Naing
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-918-4713
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.